Oguna Kasam: Landmark Achievement for Kenya – Aga Khan University Hospital Delivered First Lutetium 177 Therapy
Oguna Kasam, Senior Nuclear Medicine Technologist at Kenyatta University Teaching, Referral & Research Hospital, shared a post on LinkedIn:
“KENYA IS ON THE MAP: FIRST LUTETIUM 177 THERAPY DELIVERED TODAY.
In a historic first, Aga Khan University Hospital, East Africa in Nairobi has successfully delivered Lutetium-177 (Lu-177) therapy, marking a major milestone in Kenya’s fight against prostate cancer.
This achievement positions Kenya among Africa’s growing league of theranostics pioneers, joining South Africa, Ghana, Egypt, Algeria, and Morocco, and brings radioligand therapy closer to home for patients who once had no options.
The milestone was made possible through visionary leadership by Dr. Khalid Makhdomi and Dr. Samuel Nguku, whose earlier work also brought Sub-Saharan Africa’s first PET/CT and cyclotron at the same facility.
Great appreciation to partners Xenopia Group, NTP Radioisotopes, Umhlanga Molecular Imaging and Therapy who made this possible.
With FDA’s recent approval of Pluvicto for earlier prostate cancer radioligand therapy, Lu-177 therapy is becoming a standard of care, not a last resort. This means better outcomes, improved access, and hope for thousands.
Special gratitude to Dr. Masha Maharaj, whose unwavering support and dedication has played a pivotal role in advancing radioligand therapy across Africa and beyond. Your vision continues to shape the future of cancer care.”
Further Reading:
FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023